Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says

Executive Summary

The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.

You may also be interested in...



J&J Continues Signaling Aggressive M&A Approach To Drive Growth

Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen’s interim leader talks to Scrip; a view on Biogen and M&A; and a look at Astellas’ digital shift plans.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel